ID: h-4e806018
Hypothesis
Astrocyte-Neuron Lactate Shuttle Enhancement via Pharmacological Activation of Monocarboxylate Transporters
Astrocyte-Neuron Lactate Shuttle Enhancement via Pharmacological Activation of Monocarboxylate Transporters.
EvidencePending (0%)📖 0 cit🗣 1 debates✓ 4 support✗ 4 oppose
✓ All Quality Gates Passed
🧪 Overview
Astrocyte-Neuron Lactate Shuttle Enhancement via Pharmacological Activation of Monocarboxylate Transporters
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
flowchart TD
A["SLC16A3/MCT4<br/>Monocarboxylate Transporter"]
B["Astrocyte-Neuron<br/>Lactate Shuttle"]
C["Lactate as<br/>Energy Substrate"]
D["Neuronal Metabolic<br/>Support"]
E["Astrocyte-Neuron<br/>Metabolic Coupling"]
F["Neuroenergetic<br/>Resilience"]
G["MCT4 Activation<br/>as Metabolic Enhancer"]
A --> B
B --> C
C --> D
D --> E
E --> F
G -.->|"facilitates"| B
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7⚖️ Evidence
⚖️ Evidence Matrix4 supports4 contradicts
Supports
Metabolomic profiling of AD vs. control prefrontal cortex reveals significantly elevated lactate/creatine ratio in affected regions
Supports
Conditional MCT4 knockout in astrocytes reduces neuronal viability under metabolic stress
Supports
Lactate administration rescues memory deficits in rodent AD models through NMDAR signaling mechanisms
Supports
Human PET studies confirm reduced cerebral glucose metabolism precedes measurable cognitive decline by 5-10 years
Contradicts
The ANLS hypothesis remains contested - lactate as primary neuronal energy substrate under normal conditions lacks consensus
Contradicts
MCT4 conditional knockout does not impair baseline brain function - loss of astrocytic MCT4 in adult mice shows minimal behavioral phenotypes
Contradicts
Direct neuronal glucose oxidation is sufficient for function - neurons maintain robust oxidative metabolism without astrocyte-derived lactate
Contradicts
Lactate accumulation may drive neuroinflammation through M2 microglial polarization
📖 Linked Papers
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — SLC16A3
No curated PDB or AlphaFold mapping for SLC16A3 yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for SLC16A3 (MCT4) from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for SLC16A3 (MCT4).
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↗
Rising
7d Momentum
▲ 1.8%
Volatility
Low
0.0192
Events (7d)
3
Price History
▲44.6%💾 Resource Usage
LLM Tokens
38,010
$0.1140
Total Cost
$0.1140
🔮 Predictions
🔎 Predictions vs Observations2 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF C57BL/6 mice subjected to transient middle cerebral artery occlusion (tMCAO) receive chronic MCT4 activator treatment (10 mg/kg/day i.p.) for 14 days post-infarction, THEN motor function will impro | 30% improvement in motor coordination (rotarod latency) and normalization of striatal lactate levels to near-sham baseline, indicating restored ANLS functionali | — no observation — | pending | 0.55 |
| IF primary mouse astrocyte-neuron co-cultures are treated with a selective MCT4 agonist (10 μM, 24h), THEN extracellular lactate in the astrocyte compartment will decrease by ≥20% AND neuronal NAD+/NA | Reduced extracellular lactate in astrocyte compartment (≥20% decrease) and elevated neuronal NAD+/NADH ratio (≥15% increase), indicating enhanced lactate shuttl | — no observation — | pending | 0.65 |
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF primary mouse astrocyte-neuron co-cultures are treated with a selective MCT4 agonist (10 μM, 24h), THEN extracellular lactate in the astrocyte compartment will decrease by ≥20% AND neuronal NAD+/NADH ratio will increase by ≥15% compared to vehicle control, as measured by targeted LC-MS/MS metabol
Predicted outcome: Reduced extracellular lactate in astrocyte compartment (≥20% decrease) and elevated neuronal NAD+/NADH ratio (≥15% increase), indicating enhanced lact
Falsification: No significant change in extracellular lactate levels OR decrease in neuronal NAD+/NADH ratio OR equivalent effect observed with MCT4 knockout cells, indicating the effect is not MCT4-mediated
pendingconf 55%
IF C57BL/6 mice subjected to transient middle cerebral artery occlusion (tMCAO) receive chronic MCT4 activator treatment (10 mg/kg/day i.p.) for 14 days post-infarction, THEN motor function will improve by ≥30% on rotarod testing AND striatal lactate levels will normalize to ≤1.5-fold sham levels by
Predicted outcome: 30% improvement in motor coordination (rotarod latency) and normalization of striatal lactate levels to near-sham baseline, indicating restored ANLS f
Falsification: No significant motor improvement (rotarod latency change <15%) AND striatal lactate remains elevated (>2-fold sham) at day 14, or equivalent results in MCT4 conditional knockout mice, disproving MCT4-
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.